Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.

Original languageEnglish
Pages (from-to)2216-2219
Number of pages4
JournalBlood
Volume142
Issue number25
DOIs
StatePublished - Dec 21 2023

Fingerprint

Dive into the research topics of 'Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis'. Together they form a unique fingerprint.

Cite this